BeiGene, Ltd. (ONC)vsBio-Techne Corp (TECH)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TECH
Bio-Techne Corp
$52.69
+0.50%
HEALTHCARE · Cap: $8.20B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 340% more annual revenue ($5.34B vs $1.22B). TECH leads profitability with a 6.7% profit margin vs 5.4%. TECH trades at a lower P/E of 98.9x. TECH earns a higher WallStSmart Score of 48/100 (D+).
ONC
Hold42
out of 100
Grade: D
TECH
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
-460.5%
Fair Value
$11.32
Current Price
$52.69
$41.37 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
ROE of 4.0% — below average capital efficiency
6.7% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TECH
The strongest argument for TECH centers on Altman Z-Score, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TECH
The primary concerns for TECH are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 98.9x leaves little room for execution misses.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while TECH is a value play — different risk/reward profiles.
TECH carries more volatility with a beta of 1.48 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
TECH scores higher overall (48/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Bio-Techne Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?